← Back to patent-cliff list
Zirdafulven
Tier C — Watch / tradeZirdafulven
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RNA polymerase II, TOP2
Indications (approved)：Glioblastoma, Non-small cell lung cancer, 三阴性乳腺癌, Solid tumour, Pancreatic cancer, 横纹肌样瘤, Diffuse intrinsic pontine glioma, 室管膜瘤
Regional status
US
Phase II
2023-06-09
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zirdafulven?
Approved indications include: Glioblastoma, Non-small cell lung cancer, 三阴性乳腺癌, Solid tumour, Pancreatic cancer, 横纹肌样瘤, Diffuse intrinsic pontine glioma, 室管膜瘤.
When does the Zirdafulven patent expire?
No public expiry year is available for Zirdafulven yet; this page updates once verified.
How do I get a quote for Zirdafulven intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03